CN1693479A - Kit with fluorescent quantitative RT-PCR detection technique used for cell keratin 19(Ck19)mRNA - Google Patents
Kit with fluorescent quantitative RT-PCR detection technique used for cell keratin 19(Ck19)mRNA Download PDFInfo
- Publication number
- CN1693479A CN1693479A CN 200510037780 CN200510037780A CN1693479A CN 1693479 A CN1693479 A CN 1693479A CN 200510037780 CN200510037780 CN 200510037780 CN 200510037780 A CN200510037780 A CN 200510037780A CN 1693479 A CN1693479 A CN 1693479A
- Authority
- CN
- China
- Prior art keywords
- rna
- pipe
- water
- bottle
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A reagent kit for the fluorescent quantitative detection of cell keratin 19 (CK19) mRNA is composed of the general RNA's liquid extracts (cell cracking liquid A and B, RNA washing buffers A and B, and water without RNA enzyme), reactive liquid for reverse transcription, dNTP mixture, reversed transcriptive enzyme, PCR liquid, probe, positive standard and reference. It can be used for the diagnosis and treatment of breast cancer, small cell lung cancer, etc.
Description
Technical field
The invention belongs to biological technical field, for a kind of by fresh anticoagulation cirumferential blood is extracted total RNA, and obtain cDNA by reverse transcription mRNA sample, again in conjunction with the real-time fluorescence quantitative PCR detection technique, accurately in the detection by quantitative sample cytokeratin 19 (Cytokeratin 19, CK19) test kit of the expression amount of mRNA.
Background technology
The invention belongs to biological technical field, for a kind of by fresh anticoagulation cirumferential blood is extracted total RNA, and obtain cDNA by reverse transcription mRNA sample, again in conjunction with the real-time fluorescence quantitative PCR detection technique, accurately in the detection by quantitative sample cytokeratin 19 (Cytokeratin 19, CK19) test kit of the expression amount of mRNA.
The transfer of tumour is a great problem of clinical treatment, also is the lethal major reason of tumour.Find and make diagnosis early, the clinical treatment of tumour is selected that very important meaning is arranged, can greatly improve patient's survival rate.The discovery of metastases at present and definite mainly by clinical and pathological data, is promptly diagnosed according to iconography (X-ray sheet, CT, mr, PET etc.) or pathomorphism.But make in the imaging examination and can find focus, need a certain size metastasis formation, can be by the instrument imaging and effectively differentiate; Make on the pathomorphism whether judge malignant change of cell, then must get suitable detection sample, and have a considerable amount of observable tumour cells to exist.On this point, no matter be imaging diagnosis or pathological diagnosis, the stage that all is suitable late period after tumour forms and shifts, has had a large amount of malignant cells to accumulate, if take place to shift early stage in tumour, on pathology, can be observed or metastasis is just found before forming, and determine to shift, then can the guiding clinical treatment design for scheme, and strong prognosis foundation is provided.Hematogenous spread is one of main path of metastases, therefore in patient's peripheral blood, carry out tumour cell genetic expression detection, the tumour-specific markers product detects is an efficient manner understanding the metastases situation, so the diagnosis that the detection of tumor markers forms and shifts tumour has great help.But metastases take place early stage, tumour cell in the peripheral blood usually seldom, can't rely on the pathomorphism inspection fully, the content of tumour specific antigen also seldom simultaneously, also be difficult to detect by enzyme-labeled immunity adsorption analysis (ELISA) or radioimmunoassay methods such as (RIA) commonly used, therefore, the research to micro-tumour cell genetic expression in the circulation blood and the detection of some specificity products has caused people's extensive concern.Along with the develop rapidly of Protocols in Molecular Biology and the widespread use in medical research thereof, become and may and have been attempted by micro-tumour cell in RT-polymerase chain reaction (RT-PCR) the technology for detection peripheral blood.RT-PCR has highly sensitive and the high specific more incomparable than methods such as pathology or ELISA/RIA, for the detection of micro-tumour cell in the peripheral blood has brought hope.
The appearance of fluorescent quantitative PCR technique for we provide the accurate method of a detection by quantitative mRNA, to detecting cancer specific gene mRNA amount, has produced positive pushing effect to detect existing of circulating tumor cell.The quantitative assay of oncogene mRNA in the peripheral blood helps the early diagnosis of tumour, the judgement of the definite and prognosis of treatment plan.U.S. Applied Biosystems company had released the real-time fluorescence quantitative PCR technology in 1996, this technology has been merged advantages such as the high precision of the high specific of PCR high sensitivity, DNA hybridization and spectroscopic techniques is quantitative, the variation of fluorescent signal is to obtain quantitative results in the direct detection PCR process, do not need PCR aftertreatment or electrophoresis detection, stopped pipe operation fully, one action has overcome many difficult problems of conventional round pcr.Compare with conventional PCR, following advantage is arranged: 1, can carry out detection by quantitative accurately, can be used for being suitable for the various diseases of gene diagnosis.With detection hepatitis B HBV-DNA commonly used at present is example, it can not only detect, and hepatitis B virus intravitally duplicates patient, infectious situation, the more important thing is can be as a quantized index, can detect the intravital viral number of patient quantitatively, dynamically observe the state of an illness course of disease, observe result of treatment, an index as clinical treatment, can judge curative effect of medication, instruct the clinicist to select active drug, determine medicament, dose and the course of treatment and analyze result of treatment, determine aspects such as further treatment plan, have important and realistic meanings.2, specificity is extremely strong, has overcome false-positive main source.3, quantitatively scope is extremely wide, and sample need not to do gradient dilution.4, operation need not the PCR aftertreatment, the level of automation height rapidly.
So-called real-time fluorescence quantitative PCR technology is meant in the PCR reaction system to add fluorophor, utilizes the fluorescent signal accumulation whole PCR process of monitoring in real time, the method for by typical curve unknown template being carried out quantitative analysis at last.In fluorescent quantitative PCR technique, common preceding 15 the round-robin fluorescent signals that react with PCR are as the fluorescence background signal, the default setting of fluorescence threshold is 10 times of standard deviation of 6-15 round-robin fluorescent signal, and the cycle number that is experienced when the fluorescent signal in each reaction tubes arrived preset threshold is made as the Ct value.Studies show that there is linear relationship in the logarithm of the Ct value of each template and the initial copy number of this template, initial copy number is many more, and the Ct value is more little.Utilize the standard substance of known initial copy number can make typical curve, wherein X-coordinate is represented the logarithm of initial copy number, and ordinate zou is represented the Ct value.Therefore, as long as obtain the Ct value of unknown sample, can calculate the initial copy number of this sample from typical curve.
When adding a pair of primer, add a special fluorescent probe in the real-time fluorescence quantitative PCR amplification procedure, commonly used is the Taqman fluorescent probe at present, this probe is an oligonucleotide, and two ends are mark report fluorophor and a cancellation fluorophor respectively.When probe was complete, the reporter group fluorescent signal emitted was absorbed by quenching group, so detect less than fluorescence; In the pcr amplification process, 5 '-3 ' 5 prime excision enzyme activity of Taq enzyme is cut degraded with the probe enzyme, the report fluorophor is separated with the cancellation fluorophor, thereby the fluorescence monitoring system can receive fluorescent signal.Each working cycle detection of end first order fluorescence intensity, reaction just can obtain a working curve after finishing.
Because quantitative fluorescent PCR has good reproducibility, highly sensitive, quantitative result is characteristics accurately and reliably, so in the medical science context of detection, the problem that some conventional sense methods cann't be solved has obtained solution.For example, the morphocytology inspection can directly observe tumour cell, but because the number that tumour drops in the circulation of blood is small, and the susceptibility of this inspection and specificity are all relatively poor, positive rate is low.The application that immunohistochemical method has improved tumour cell painted specificity, particularly monoclonal antibody in the circulation of blood makes painted specificity and susceptibility that bigger improvement arranged, and can find 10
4-10
5A tumour cell in the individual karyocyte.But this technology then needs specific antibody, the production relative complex.Simultaneously, false positive has limited this broad application.Compare with these technology, quantitative fluorescent PCR has tangible advantage, because the adjusting of most of genes betides transfer level, some tumour can be transcribed specific mrna, but it is synthetic not have corresponding protein, so the quantitative fluorescent PCR range of application is wider; PCR is simple and easy to do, as long as know the testing gene sequence, can design synthetic primer and carry out reverse transcription and amplification; This method has higher sensitivity and repeatability, has also guaranteed the accuracy of medical science detected result.So this The Application of Technology will be found small transfer to the tumour cell in the circulation of blood of early stage searching tumour patient, for guiding clinical treatment, improve patient's prognosis and produce very important effect.
There is more specific expression in CK19 in mammary cancer, small cell lung cancer cell, CK19mRNA can be used as the sign of cancer cells in mammary cancer, small cell lung cancer patient marrow and the blood.It is significant for dynamic observing of diagnosis, transfer, recurrence, treatment effectiveness evaluation and the state of an illness of mammary cancer, small cell lung cancer to detect CK19mRNA in mammary cancer, small cell lung cancer patient marrow and the blood.
Summary of the invention
Test kit of the present invention comprises: cell pyrolysis liquid I, cell pyrolysis liquid II, RNA lavation buffer solution I, RNA lavation buffer solution II, the water of no RNA enzyme, RNA separator column, reverse transcription damping fluid, reversed transcriptive enzyme storage liquid, dNTP mixture, PCR reaction solution, probe, standard substance, reference substance.More than various solution be the aqueous solution.
(1), cell pyrolysis liquid I comprises: 0.1mol/L Tris-HCl (Tutofusin tris-hydrochloric acid, pH7.6,25 ℃), 0.1mol/L sodium-chlor, 0.05mol/L magnesium chloride, water.
(2), cell pyrolysis liquid II comprises: 3mol/L guanidinium isothiocyanate, 2mol/L Guanidinium hydrochloride, 0.3mol/L sodium-acetate (pH5.2), 0.2% (W/V) SDS (sodium lauryl sulphate), water.
(3), RNA lavation buffer solution I:0.2mol/L sodium-acetate (pH5.2), 0.1mol/L sodium chlorate, 0.1mol/LTris-HCl (pH7.5,25 ℃), water.
(4), RNA lavation buffer solution II:1.2mol/L Trisodium Citrate, 0.5mol/L Tris-HCl (pH7.5,25 ℃), water.
(5), the water preparation method of no RNA enzyme adds DEPC (diethylpyrocarbonate) to deionized water, to final concentration be 0.05% (V/V), room temperature (22-25 ℃) was placed after 10-12 hour, 121 ℃, the 20min high pressure, room temperature is placed standby.
(6), the RNA separator column is a kind of silicagel column, available from U.S. Omega biotech company (Hibind-V post), this post adopts Hibind silica matrix film combination technology, can specificity in conjunction with RNA, and used water eluted rna reaches the purpose of separation and purification RNA.
(7), the reverse transcription damping fluid comprises: 9.1 μ mol/L Oligo (dT)
12-18, 3.6U/ μ l Rnase Inhibitor, 72.7mmol/L DTT (dithiothreitol (DTT)), 182mmol/L Tris-HCl (8.3,25 ℃ of pH), 273mmol/L KCl, 11mmol/L MgCl
2, water.
(8), the reversed transcriptive enzyme storage liquid comprises: 20mmol/L Tris-HCl (7.5,25 ℃ of pH), 100mmol/L NaCl, 0.1mmol/L EDTA, 1.0mmol/L DTT, 50% (V/V) glycerine, 0.01% (V/V) Nonidet p-40,200U/ μ l reversed transcriptive enzyme (M-MLV), water.
(9), the dNTP mixture comprises: dATP, dCTP, dGTP, dTTP, be its sodium salt-aqueous solution pH7.0-7.5, four kinds of dNTP concentration are 10mmol/L.
As dATP is deoxyadenosine triphosphate, and its sodium salt is that in three hydrogen on the phosphoric acid one or two replaced by sodium, just formed sodium salt; It also is like this that other youngster plants.Be that dNTP exists with sodium-salt form.
(10), the PCR reaction solution comprises: 18.5mmol/L Tris-HCl (pH8.3,25 ℃), 2.78mmol/L MgCl
2, 92.6mmol/L KCl, upstream and downstream primer (0.37 μ mol/L), 0.1U/ μ l Taq enzyme, dNTP mixture (dGTP, dTTP, its concentration is 400nmol/L for dATP, dCTP), water.
Detection is used the downstream primer sequence and is respectively:
P1：5’-ACT?ACA?GCC?ACT?ACT?ACA?CGA?C-3’，
P2：5’-CAG?AGC?CTG?TTC?CGT?CTC?AAA?C-3’
(11), probe is fluorescence labeling probe, its sequence is:
5’-FAM-TCT?GGC?TGC?AGA?TGA?CTT?CCG?AAC?CA-TAMRA-3’
The concentration of probe is: 2 μ mol/L, TE (10mmol/L Tris-HCl, 1mmol/L EDTA, water) dissolving.
(12), the sequence of standard substance is:
1???CAGAGCCTGT??TCCGTCTCAA??ACTTGGTTCG??GAAGTCATCT??GCAGCCAGAC
51??GGGCGTTGTC??GATCTGCAGG??ACAATCCTGG??AGTTCTCAAT??GGTGGCACCA
101?AGAATCTTGT??CCCGCAGGTC??CTGGATGGTC??GTGTAGTAGT??GGCTGTAGT
The concentration of standard substance is: 10
6Copies/ μ l, TE (10mmol/L Tris-HCl, 1mmol/L EDTA, water) dissolving.
(13), reference substance is divided into positive reference substance and negative control product, positive reference substance is the sample (10 that CK19cDNA is arranged
4Copies/ μ l, the TE dissolving), the negative control product are the reverse transcription product of the total RNA of normal people's peripheral blood.
The specification of test kit of the present invention is: 10 person-portions/box; The amount of each component is in every box: cell pyrolysis liquid I1 bottle (30ml/ bottle), cell pyrolysis liquid II1 bottle (10ml/ bottle), RNA lavation buffer solution I1 bottle (10ml/ bottle), RNA lavation buffer solution IIl bottle (3ml/ bottle), 1 bottle in no RNA enzyme water (2ml/ bottle), RNA separator column (10), reverse transcription damping fluid 1 pipe (27.5ul/ pipe), dNTP mixture 1 pipe (5ul/ pipe), reversed transcriptive enzyme 1 pipe (2.5ul/ pipe), PCR reaction solution 1 pipe (216ul/ pipe), probe 1 pipe (24ul/ pipe), standard substance 1 pipe (10ul/ pipe), positive reference substance 1 pipe (10ul/ pipe), negative control product 1 pipe (10ul/ pipe).
This reagent total RNA extraction reagent is stored in room temperature (22-25 ℃); RT-PCR reagent is stored in-20 ℃, reduces multigelation as far as possible.
The present invention has set up the method for utilizing TaqMan technology for detection CK19mRNA to express, and patient's sample after testing, shows that this method is practical.Because present method has adopted the pcr amplification technology, the detection sensitivity that makes CK19mRNA express improves greatly, and because the application of fluorescent probe, make its specificity improve greatly, reduced the false positive rate of conventional pcr amplification, make us can obtain enough information in the sample of minute quantity, the total RNA extraction reagent among the present invention and at present conventional RNA extract the reagent following advantage of having compared: (1). and easy and simple to handle; (2). safe in utilization, operating process does not have organic solution and pollutes; (3). extract fully, sophistication and high-quality reagent guarantee that sample RNA extracts fully; (4). gained RNA purity height.Primer, probe and detected result that present method is designed can provide reliable foundation for the exploitation of fluorescent quantificationally PCR detecting kit.
In this test item, we have adopted the most advanced at present real-time fluorescence quantitative PCR detection technique, reduce false-positive interference under the prerequisite that keeps hypersensitivity as far as possible.Before the real-time fluorescence quantitative PCR detection technique occurs, people quantitatively will pass through PCR product electrophoresis to pcr template, again with electrophoresis result machine picture processing as calculated, determine what of final PCR product amount according to the brightness of electrophoretic band, or the PCR product of the tape label mode with ELISA detected, infer the amount that starting template more thus, but these methods in fact all belong to the sxemiquantitative level, even because PCR condition optimization, the unstable of the operation of electrophoresis and subsequent step brings influence still can for result's analysis, thereby influences quantitative this purpose.Appearance along with the real-time fluorescence quantitative PCR technology, people can accomplish the accurate quantification to pcr template veritably, this high sensitivity that has quantitatively not only kept conventional PCR, and because specificity fluorescent probe hybridization The Application of Technology makes the specificity of detected gene improve greatly.
The using method of test kit of the present invention:
Each detection all should be set up positive control and negative control.
[sample requirement]
The fresh peripheral blood or the sample of bone marrow of 3 milliliters of EDTA anti-freezings.
Adopt venous blood or marrow 3ml in 5 or the aseptic centrifuge tube of 10ml in, use EDTA to make antithrombotics (1.44mg/ml whole blood).Should use immediately after the sample collection, if can not use immediately, can preserve 1-2 hour, but the time should not be after length, otherwise will influence measurement result at 4 ℃.Whole blood after treatment, the karyocyte that obtains can be stored in the several months in-80 ℃ or the liquid nitrogen, can not influence measurement result.
[operation steps]
One, experiment is prepared
1. cell pyrolysis liquid I is diluted to cell pyrolysis liquid I diluent in 1: 10 ratio with the sterilization deionized water.
2. add 2 mercapto ethanol in cell pyrolysis liquid II, add-on is the 2 mercapto ethanol (concentration of commercial solution is generally 14.5mM) that every 1ml cell pyrolysis liquid II adds 20 μ l, and the packing 2 mercapto ethanol will carry out under ventilating kitchen.
3.RNA the indication that lavation buffer solution II before using, presses on the label adds dehydrated alcohol.
Two, total RNA extracts
1. the cell pyrolysis liquid I diluent that in the 50ml centrifuge tube of handling once autoclaving, adds fresh anticoagulated blood of 3ml and 15ml, the vortex oscillation mixing.
2. ice bath is 15 minutes, rapid mixing twice on the vortex oscillation device, and the solution becomes clarification shows red corpuscle cracking.If the hemocytometer of individual samples when perhaps ECR raises, can prolong ice bath time to 20 minute.
3. 4 ℃, 450g, centrifugal 10 minutes precipitation karyocytes discard the supernatant that contains splitting erythrocyte fully.
4. with the cell pyrolysis liquid I diluent washing precipitation karyocyte of 6ml, vortex oscillation is with complete suspension cell.
5. 4 ℃, 450g, centrifugal 10 minutes, and remove supernatant once more.
6. add 650 μ l cell pyrolysis liquid II (having added 2 mercapto ethanol) in agglomerating karyocyte, the abundant mixing of vortex oscillation is transferred to the 1.5ml centrifuge tube of a no RNA enzyme with it.
7. add isopyknic 70% ethanol, the vortex oscillation mixing.May produce throw out this moment owing to alcoholic acid adds, but this can not influence the extraction of RNA.
8. above-mentioned mixed solution (not comprising precipitation) is added to that (this post maximum binding capacity is 800 μ l on the RNA separator column that is fixed on the 2ml collection tube, so each amount that adds should not surpass 750 μ l), 10000g centrifugal 1 minute, discards flowing liquid and proceeds the operation of step 8.
9. drawing 750 μ l RNA lavation buffer solution I directly is added on the RNA separator column and washs pillar.As above method is centrifugal and discard the 2ml collection tube.
10. pillar is installed to new 2ml collection tube, add the RNA lavation buffer solution II of 500 μ l with alcohol dilution, 10000g, centrifugal 1 minute, discard effluent liquid, reuse this collection tube.
11. it is, centrifugal and discard effluent liquid again with the RNA lavation buffer solution II of 500 μ l washing pillar.The centrifugal pillar of 12000g dried RNA separator column matrix in 1 minute one then.
12. eluted rna.The water elution RNA that posts transfer is not also had the RNA enzyme to the 1.5ml centrifuge tube (test kit does not provide) of no RNA enzyme with 50 μ l.The water of guaranteeing the no RNA enzyme that adds directly is added on the base for post matter centrifugal 1 minute of 10000g.Place on the ice chest centrifuge tube that RNA is housed standby.
Three, RT-PCR
1. the centrifuge tube that reverse transcription damping fluid, dNTP mixture, reversed transcriptive enzyme storage liquid will be housed takes out from-20 ℃, place treat on the ice chest that it slowly melts after, of short duration centrifugal, with pipettor dNTP mixture and reversed transcriptive enzyme storage liquid are all added in the reverse transcription damping fluid pipe and to be mixed with inverse transcription reaction liquid, mixing, of short duration centrifugal, place on the ice chest standbyly, use back residue inverse transcription reaction liquid can put into-20 ℃ of refrigerators and preserve.
According to the form below preparation reverse transcription system
Inverse transcription reaction liquid 3.5ul
Total rna solution 2.0ul
The water 4.5ul of no RNA enzyme
The reverse transcription reaction condition: 50 ℃ 10 minutes, take out and to place on the ice chest.
2. by following composition preparation PCR reaction solution:
Reverse transcription product 10ul
PCR reaction solution 13.5ul
Probe 1.5ul
The PCR reaction conditions: 95 ℃ 10 minutes; (95 ℃ 15 seconds, 61 ℃ 1 minute, 50 circulations).
Four, the making of typical curve
With standard substance stock solution (2 * 10
6Copies/ul) gradient dilution is 2 * 10
5, 2 * 10
4, 2 * 10
3, 2 * 10
2, 2 * 10
1Copies/ul, getting 5ul is that template (adding water 5ul, the same table of other components) is together carried out pcr amplification with testing sample, the quantitative curve of production standard.
[result's judgement]
1. use the accompanying software of real-time fluorescence quantitative PCR instrument to carry out the preservation of file and the setting of threshold value.
2. choose the hole and the labeled standards value of different concns standard substance correspondence, use corresponding the analysis, draw typical curve and relevant information.
3. choose all samples to detect the hole, use corresponding the analysis, draw the starting template number (M) of testing sample.
4. copy number N=M * 25/3 of AFP mRNA in every milliliter of whole blood sample.
Description of drawings
Fig. 1 detects figure for sample standard.
Fig. 2 is the sample standard graphic representation.
Embodiment
Embodiment 1
The real-time fluorescence quantitative RT-PCR method detects expression and the application of human peripheral CK19mRNA
One, material:
Total RNA extraction reagent, RT and PCR damping fluid, competence bacterium (DH5 α) produces for Hefei ZhongKeDa Bioisystech Co., Ltd, DEPC (diethylpyrocarbonate) is available from Biobasic company, the M-MLV reversed transcriptive enzyme is available from Invitrogen company, the Taq enzyme, Oligo (dT), the T-carrier, the regular-PCR amplification kit is available from Takara company, DTT (dithiothreitol (DTT), 0.1M) available from Invitrogen company, DNA gelextraction kit, plasmid reclaims reagent in a large number available from the clean biochemical technology of Hangzhou Wei Te company limited, 1-15K type trace high speed low temperature centrifugal machine, 2-5 type low speed normal temperature whizzer is available from German Sigma company, the hypervelocity refrigerated centrifuge is available from German Hettich company, 3111 type thermostat(t)ed water shell type C02 incubators are available from U.S. Forma company, Ultralow Temperature Freezer is available from Japanese SANYO company, Bechtop is available from the sincere biological plant of Shanghai intelligence company, Biometra PCR instrument is available from Biometra company, sequencing reagent, 377 sequenators, available from U.S. Applied Biosystems company.
Two, primer and probe design and synthetic:
With the CK19 full length cDNA sequence is template, use 7000 type real-time fluorescence quantitative PCR instrument (U.S. Applied Biosystems company) accompanying software to analyze TaqMan primer and probe site, consider CK19 genomic dna sequence situation simultaneously, therefrom select best of breed.
The standard substance primer sequence is identical with the PCR primer sequence with detection, and the upstream and downstream primer sequence is respectively:
P1:5 '-ACTACAGCCACTACTACACGAC-3 ', P2:5 '-CAGAGCCTGTTCCGTCTCAAAC-3 ', the fluorescent probe sequence is: 5 '-FAM-TCT GGC TGC AGA TGA CTT CCG AAC CA-TAMRA-3 ' all has Shanghai to give birth to worker company and synthesizes.
Three, detection prepares with standard substance:
1. the extraction of cell total rna
Testing used cell is the MCF-7 cell, 0.25% tryptic digestion, and the 1000rpm centrifugal collecting cell is transferred in the Eppendorf pipe, and every pipe has 1 * 10 approximately
6Individual cell.Operate by above-mentioned method for extracting total RNA step 6-step 12.
2. reverse transcription reaction
The centrifuge tube that reverse transcription damping fluid, dNTP mixture, reversed transcriptive enzyme are housed is taken out from-20 ℃, place treat on the ice chest that it slowly melts after, of short duration centrifugal, with pipettor dNTP mixture and reversed transcriptive enzyme are all added in the reverse transcription damping fluid pipe and to be mixed with inverse transcription reaction liquid, mixing, of short duration centrifugal, place on the ice chest standbyly, use back residue inverse transcription reaction liquid can put into-20 ℃ of refrigerators and preserve.
According to the form below preparation reverse transcription system
Inverse transcription reaction liquid 3.5ul
Total rna solution 2.0ul
The water 4.5ul of no RNA enzyme
The reverse transcription reaction condition: 50 ℃ 10 minutes, take out and to place on the ice chest
3.PCR amplification
(annotate: the pcr amplification agents useful for same is the regular-PCR amplification kit available from Takara company herein)
Prepare the PCR reaction solution by following composition:
Reverse transcription product 10ul
10×buffer????????????5.0ul
dNTPmix???????????????4.0ul
Upstream and downstream primer 2 .0ul
Taq enzyme 0.5ul
Water 28.5ul
The PCR reaction conditions: 94 ℃ 5 minutes; (94 ℃ 15 seconds, 61 ℃ 1 minute, 72 ℃ 50 seconds, 35 circulations).
4.CK19 the acquisition of amplified production:
Prepare 1.2% sepharose, with gained PCR product electrophoresis, cut the agar that contains target DNA under ultraviolet lamp, after drying with paper handkerchief, chopping is weighed, and determines the volume of glue according to the ratio of 100mg=100 μ l; Add DE-A liquid according to the ratio in the DNA gel extraction kit specification sheets, 60 ℃ of heating are melted fully; Add 0.5 times of volume in the DE-B of DE-A liquid liquid mixing, add Virahol to 20% of final volume; Aforesaid liquid is changed in the preparation pipe, and the centrifugal 1min of 3600rpm abandons filtrate after repeating once; After adding 0.5ml W1, the centrifugal 30s of 3600rpm abandons filtrate; Add 0.7ml W2, the centrifugal 30s of 3600rpm repeats once after abandoning filtrate; The centrifugal 1min of 12000rpm; The pipe of purchasing is placed new 1.5ml centrifuge tube, adds 25 μ l water or elutriants in pipe center, leave standstill 1min after, (12000rpm) centrifugal 1min DNA that can obtain to reclaim the most at a high speed.
5.CK19 the clone of amplified production and evaluation:
The structure of recombinant C K19 cloning vector: in the 10 μ l systems, add 1 μ lT-carrier, 4 μ l DNA samples add 5 μ l and connect buffer, 16 ℃ of connections of spending the night; Get 5 μ l and connect product, join in the 200 μ l competent cells, ice bath 40min behind the mixing places 42 ℃ of water heat-shocked 90s, ice bath 2min; The LB substratum 800 μ l that add antibiotic-free, the speed with 100-150rpm on 37 ℃ of shaking tables is mixed jolting 45min; Centrifugal back is inhaled and is removed 800 μ l supernatants, and remaining 200 μ l are coated on the LA flat board equably, is inverted cultivation 10-14 hour after keeping flat 20min for 37 ℃.
The evaluation of recombinant vectors: (extracting method of plasmid/PCR identify): observe the bacterium colony on the LA flat board, the picking bacterium colony preferably of looking goes to respectively in the Boiling tube that 5ml LA substratum is housed at random, and jolting is about 14 hours, to OD in the rearmounted 37 ℃ of shaking tables of numbering
600During ≈ 4, about 1.5ml culture is changed in the centrifuge tube, 4 ℃, the centrifugal 30s of 11000rpm is resuspended in precipitation among the alkaline lysis liquid I of 100 μ l precoolings the thermal agitation mixing; The alkaline lysis liquid II that adds the new configuration of 200 μ l, ice bath 3min behind the mixing; The alkaline lysis liquid III that adds 150 μ l precoolings puts upside down ice bath 3-5min behind the mixing; 4 ℃, supernatant is transferred in another centrifuge tube behind the centrifugal 5min of 11000rpm; Add isopyknic phenol/chloroform (1: 1), vibrate back 4 ℃, the centrifugal 2min of 11000rpm, supernatant is transferred to another centrifuge tube; Add 3M NaAc solution and 2.5 times of dehydrated alcohols of 1/10 volume, room temperature leaves standstill 10min behind the mixing; 4 ℃, abandon supernatant behind the centrifugal 10min of 11000rpm, add 1ml 70% ethanol in the precipitation, after the vibration rinsing 4 ℃, the centrifugal 2min of 11000rpm; Discard and add a small amount of dehydrated alcohol behind the supernatant liquid, 4 ℃, the centrifugal 2min of 11000rpm, discard ethanol after, room temperature leaves standstill, and behind the volatilization ethanol, adds 30 μ l dissolved in distilled water DNA.Get an amount of DNA and carry out pcr amplification, determine by electrophoretic image whether the bacterium colony of getting is desired purpose bacterium colony.
6. a large amount of extractings of plasmid:
After identifying that institute's bacterium colony is the purpose bacterium colony, get the long bacterium liquid that the purpose bacterium colony is arranged of 1ml, join in the 30ml LB substratum, shaking table is cultured to OD
600Be about 0.6, get the above-mentioned bacterium liquid of 25ml and be seeded in the 300ml LB substratum 37 ℃ of overnight incubation (300rpm).4 ℃ of following 4500rpm, 20min receives bacterium, and thalline is suspended among the STE of 200ml precooling, 4 ℃ of following 4500rpm, 20min receives bacterium, and thalline adds 9ml Solution I, mixing adds the lml freshly prepared N,O-Diacetylmuramidase of 10mmol/L Tris-HCl (pH8.0) (10mg/ml).Add the freshly prepared SolutionII of 10ml, mixing is 5-7 time gently, and room temperature left standstill 5 minutes, the ice-cold SolutionIII of adding 7.5ml, and mixing gently, ice bath 10 minutes, centrifugal 10 minutes of 4 ℃ of following 11000rpm get supernatant.The Virahol that adds 2/3 volume, mixing, room temperature left standstill 10 minutes, centrifugal 10 minutes of 11000rpm abandons supernatant, precipitates with 70% washing with alcohol, 8000rpm, the centrifugal recovery of 15min is with 2ml TE dissolution precipitation, the LiCl that adds 2ml 5mol/L, mixing, centrifugal 10 minutes of 10000g, supernatant discarded, with 70% washing with alcohol precipitation, evaporate to dryness.Add 300 μ l TER, dissolution precipitation is transferred to Eppendorf pipe, 37 ℃ water-bath 1-2 hour, add 300 μ l 1.6mol/L NaCl (containing 13% polyoxyethylene glycol), mixing, centrifugal 15 minutes of 4 ℃ of following 12000rpm abandon supernatant.Precipitation is dissolved among the 250 μ l TE (pH8.0), uses phenol, phenol/chloroform, each extracting of chloroform respectively once.Get supernatant, add 60 μ l 10mol/l NH
4The dehydrated alcohol of Ac and 2 times of volumes (or 95% ethanol), mixing, centrifugal 5 minutes of 4 ℃ of following 12000g abandon supernatant.120 μ l, 75% washing with alcohol precipitation, centrifugal 10 minutes of 4 ℃ of following 12000g abandon supernatant.Control dry liquids, room temperature leaves standstill to drying as far as possible.Add 100 μ l tri-distilled water dissolution precipitations, ultraviolet spectrophotometer detects the concentration and the purity of plasmid down.
7. the mensuration of plasmid sequence
The plasmid of above-mentioned preparation carries out sequencing with 377 sequenators of U.S. Applied Biosystems company.
Four, sample detects
The patient with breast cancer that 56 examples are made a definite diagnosis through pathology is experimental group, and wherein 38 examples are made a definite diagnosis for pathological diagnosis lymphoglandula or far-end transfer are taken place, and 18 examples for pathological diagnosis lymphoglandula do not take place or far-end shifts; 18 routine healthy blood donors and the optimum patient of 16 routine mammary gland are control group.It is sample that every routine experimenter gets the fresh anticoagulation cirumferential blood of 3ml.Use test kit of the present invention and carry out the cell total rna extraction, get 2 μ lRNA, carry out reverse transcription in 10 μ l total reaction systems after, use downstream primer and probe in the enterprising performing PCR amplification of the quantitative pCR instrument of ABI company 7000 types with detecting, condition is 95 ℃ of sex change in 10 minutes; 95 ℃ 15 seconds, 60 ℃ were carried out 50 circulations in 1 minute.Add standard substance production standard curve simultaneously.The result handles according to typical curve through instrument and calculates the expression amount that detects sample CK19mRNA.
Experimental result
One, the preparation of standard substance
Through order-checking, the standard substance of above-mentioned design conform to expection fully, the standard substance fragments sequence of recovery following (for inserting the fragment in the T carrier):
1???CAGAGCCTGT??TCCGTCTCAA??ACTTGGTTCG??GAAGTCATCT??GCAGCCAGAC
51??GGGCGTTGTC??GATCTGCAGG??ACAATCCTGG??AGTTCTCAAT??GGTGGCACCA
101?AGAATCTTGT??CCCGCAGGTC??CTGGATGGTC??GTGTAGTAGT??GGCTGTAGT
Two, sample detection:
1. standard testing result is seen Fig. 1, and typical curve is seen Fig. 2.
2. real-time fluorescence quantitative RT-PCR detects the expression of CK19mRNA in the breast cancer disease human peripheral, and concrete outcome is as follows:
| The sample source | The example number | The CK19 number positive | ??％ |
| Pathological diagnosis lymphoglandula or far-end have metastatic lymph node or far-end not to have the optimum patient health blood donor of the contrast of transfer mammary gland | ? ??38 ??18 ? ??16 ??18 | ? ??37 ??14 ? ??1 ??0 | ? ??94.7 ??77.8 ? ??6.3 ??0 |
Claims (2)
1. cytokeratin 19 (CK19) mRNA fluorescence quantitative RT-PCR detecting kit, it is characterized by: it comprises cell pyrolysis liquid I, cell pyrolysis liquid II, RNA lavation buffer solution I, RNA lavation buffer solution II, the water of no RNA enzyme, RNA separator column, reverse transcription damping fluid, dNTP mixture, reversed transcriptive enzyme storage liquid, PCR reaction solution, probe, standard substance, reference substance; More than various solution solvent for use be water;
(1), cell pyrolysis liquid I comprises 0.1mol/L Tris-HCl (Tutofusin tris-hydrochloric acid, pH7.6,25 ℃), 0.1mol/L sodium-chlor, 0.05mol/L magnesium chloride, water;
(2), cell pyrolysis liquid II comprises 3mol/L guanidinium isothiocyanate, 2mol/L Guanidinium hydrochloride, 0.3mol/L sodium-acetate (pH5.2), 0.2% (W/V) SDS (sodium lauryl sulphate), water;
(3), RNA lavation buffer solution I comprises 0.2mol/L sodium-acetate (pH5.2), 0.1mol/L sodium chlorate, 0.1mol/LTris-HCl (pH7.5,25 ℃), water;
(4), RNA lavation buffer solution II comprises 1.2mol/L Trisodium Citrate, 0.5mol/L Tris-HCl (pH7.5,25 ℃), water;
(5), the water of no RNA enzyme makes by following method: add DEPC (diethylpyrocarbonate) to deionized water, to final concentration be 0.05% (V/V), room temperature (22-25 ℃) was placed after 10-12 hour, 121 ℃, the 20min high pressure, room temperature is placed standby;
(6), the RNA separator column is a kind of silicagel column, can specificity in conjunction with RNA, and used water eluted rna reaches the purpose of separation and purification RNA;
(7), the reverse transcription damping fluid comprises 9.1 μ mol/L Oligo (dT)
12-18, 3.6U/ μ l Rnase Inhibitor, 72.7mmol/L DTT (dithiothreitol (DTT)), 182mmol/L Tris-HCl (pH8.3,25 ℃), 273mmol/L KCl, 11mmol/L MgCl
2, water;
(8), the reversed transcriptive enzyme storage liquid comprises 20mmol/L Tris-HCl (pH7.5,25 ℃), 100mmol/L NaCl, 0.1mmol/L EDTA, 1.0mmol/L DTT, 50% (V/V) glycerine, 0.01% (V/V) Nonidet p-40,200U/ μ l reversed transcriptive enzyme (M-MLV), water;
(9), the dNTP mixture comprises dATP, dCTP, dGTP, dTTP, is its sodium salt-aqueous solution, pH7.0-7.5, four kinds of dNTP concentration are 10mmol/L;
(10), the PCR reaction solution comprises 18.5mmol/L Tris-HCI (pH8.3,25 ℃), 2.78mmol/L MgCI
2, 92.6mmol/L KCI, upstream and downstream primer (0.37 μ mol/L), 0.1U/ μ l Taq enzyme, dNTP mixture (dGTP, dTTP, its concentration is 400nmol/L for dATP, dCTP), water;
The upstream and downstream primer sequence is respectively:
P1：5’-ACT?ACA?GCC?ACT?ACT?ACA?CGA?C-3’，
P2：5’-CAG?AGC?CTG?TTC?CGT?CTC?AAA?C-3’
(11), probe is fluorescence labeling probe, its sequence is:
5’-FAM-TCT?GGC?TGC?AGA?TGA?CTT?CCG?AAC?CA-TAMRA-3’
The concentration of probe is: 2 μ mol/L, TE (10mmol/L Tris-HCl, 1mmol/L EDTA, water) dissolving;
(12), the sequence of standard substance is respectively:
1????CAGAGCCTGT?TCCGTCTCAA?ACTTGGTTCG?GAAGTCATCT?GCAGCCAGAC
51???GGGCGTTGTC?GATCTGCAGG?ACAATCCTGG?AGTTCTCAAT?GGTGGCACCA
101??AGAATCTTGT?CCCGCAGGTC?CTGGATGGTC?GTGTAGTAGT?GGCTGTAGT
Its concentration is: 10
6Copies/ μ l, TE (10mmol/L Tris-HCl, 1mmol/L EDTA, water) dissolving;
(13), reference substance is divided into positive reference substance and negative control product, positive reference substance is the sample (10 that CK19 cDNA is arranged
4Copies/ μ l, the TE dissolving), the negative control product are the reverse transcription product of the total RNA of peripheral blood.
2. cytokeratin 19 according to claim 1 (CK19) mRNA fluorescence quantitative RT-PCR detecting kit, it is characterized in that: the specification of test kit of the present invention is 10 person-portions/box; The amount of each component is in every box, cell pyrolysis liquid I1 bottle (30ml/ bottle), cell pyrolysis liquid II1 bottle (10ml/ bottle), RNA lavation buffer solution I1 bottle (10ml/ bottle), RNA lavation buffer solution II1 bottle (3ml/ bottle), 1 bottle in no RNA enzyme water (2ml/ bottle), RNA separator column (10), reverse transcription damping fluid 1 pipe (27.5ul/ pipe), dNTP mixture 1 pipe (5ul/ pipe), reversed transcriptive enzyme 1 pipe (2.5ul/ pipe), PCR reaction solution 1 pipe (216ul/ pipe), probe 1 pipe (24ul/ pipe), standard substance 1 pipe (10ul/ pipe), positive reference substance 1 pipe (10ul/ pipe), negative control product 1 pipe (10ul/ pipe).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100377808A CN100371459C (en) | 2005-02-01 | 2005-02-01 | Kit with fluorescent quantitative RT-PCR detection technique used for cell keratin 19(Ck19)mRNA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100377808A CN100371459C (en) | 2005-02-01 | 2005-02-01 | Kit with fluorescent quantitative RT-PCR detection technique used for cell keratin 19(Ck19)mRNA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1693479A true CN1693479A (en) | 2005-11-09 |
| CN100371459C CN100371459C (en) | 2008-02-27 |
Family
ID=35352605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100377808A Expired - Fee Related CN100371459C (en) | 2005-02-01 | 2005-02-01 | Kit with fluorescent quantitative RT-PCR detection technique used for cell keratin 19(Ck19)mRNA |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100371459C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102286473A (en) * | 2011-09-08 | 2011-12-21 | 苏州大学 | Reagent kit for directly carrying out nucleic acid amplification from whole blood sample and method |
| CN101659959B (en) * | 2008-08-29 | 2012-06-27 | 上海裕隆生物科技有限公司 | Expression vector for recombinant human keratin 19 antigen active fragments, and application thereof |
| CN102719358A (en) * | 2007-01-15 | 2012-10-10 | 希森美康株式会社 | Method of judging lymph node metastasis of stomach cancer using cytokeratin 19 |
| CN101101288B (en) * | 2006-07-03 | 2012-12-12 | 希森美康株式会社 | Cancer transfer determining method and device thereof |
| CN103184198A (en) * | 2011-12-30 | 2013-07-03 | 思洛生物技术股份有限公司 | Reagent and method for improving reverse transcriptase performance |
| CN109207589A (en) * | 2017-07-05 | 2019-01-15 | 安徽普元生物科技股份有限公司 | The kit of one-step method real-time fluorescent quantitative reverse transcription polymerase chain reaction detection people's cell Keratin 7 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1138780A1 (en) * | 2000-03-31 | 2001-10-04 | Boehringer Mannheim Gmbh | Detection of disseminated tumor cells by quantitative RT-PCR of cytokeratin 20 mRNA |
| DE10224534A1 (en) * | 2002-05-31 | 2003-12-11 | Juergen Dolderer | Method for diagnosing colorectal cancer in a tissue sample and treatment means |
| CN1176221C (en) * | 2002-11-12 | 2004-11-17 | 浙江大学医学院附属第二医院 | Real time fluorescent quantitative RT-PCR detecting human cell keratin 19 reagent box |
-
2005
- 2005-02-01 CN CNB2005100377808A patent/CN100371459C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101101288B (en) * | 2006-07-03 | 2012-12-12 | 希森美康株式会社 | Cancer transfer determining method and device thereof |
| CN102719358A (en) * | 2007-01-15 | 2012-10-10 | 希森美康株式会社 | Method of judging lymph node metastasis of stomach cancer using cytokeratin 19 |
| CN101659959B (en) * | 2008-08-29 | 2012-06-27 | 上海裕隆生物科技有限公司 | Expression vector for recombinant human keratin 19 antigen active fragments, and application thereof |
| CN102286473A (en) * | 2011-09-08 | 2011-12-21 | 苏州大学 | Reagent kit for directly carrying out nucleic acid amplification from whole blood sample and method |
| CN103184198A (en) * | 2011-12-30 | 2013-07-03 | 思洛生物技术股份有限公司 | Reagent and method for improving reverse transcriptase performance |
| CN109207589A (en) * | 2017-07-05 | 2019-01-15 | 安徽普元生物科技股份有限公司 | The kit of one-step method real-time fluorescent quantitative reverse transcription polymerase chain reaction detection people's cell Keratin 7 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100371459C (en) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102149827B (en) | Use of MiR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy | |
| CN107988325B (en) | RAA constant temperature fluorescence detection method and reagent for shrimp liver Enterocytozoon (EHP) | |
| CN1324146C (en) | Fluorescent quantitative PT-PCR detection kit for detecting BCR-ABL fusion gene (P210bcr/abl)mRNA | |
| CN104046700B (en) | The detection kit of a kind of Rapid identification donkey hide, horse skin and mule skin | |
| CN107828914B (en) | RAA constant temperature fluorescence detection method and reagent for Infectious Hypodermal and Hematopoietic Necrosis Virus (IHHNV) | |
| CN1693479A (en) | Kit with fluorescent quantitative RT-PCR detection technique used for cell keratin 19(Ck19)mRNA | |
| CN107828915A (en) | Shrimp cream head virus（YHV）RAA constant temperature fluorescence detection method and reagent | |
| CN1712547A (en) | Fluorescent quantitative RT-PCR detecting kit of 2-f(o)etoprotein (AFP)mRNA | |
| WO2016075277A1 (en) | Novel fish virus and method for detection | |
| CN107815498A (en) | The SNP marker related to the multiple economic characters of pig and its application | |
| CN110438260A (en) | A kind of African swine fever virus nucleic acid test strips detection kit | |
| JP7090357B2 (en) | Use of primer sets, kits, and microRNA serum markers and primer sets to identify the sex of sturgeon | |
| CN103276099A (en) | Primer and kit for fluorescent quatititive PCR (polymerase chain reaction) detection of helicobacter pylori | |
| CN101045939A (en) | HBV DNA gene subtype detecting method and kit | |
| CN105483246B (en) | Application of the differential expression of gene in carcinoma of mouth diagnosis | |
| CN1560279A (en) | Reagent for testing foot and mouth disese virus by fluorescent quantity RI-PCR and its preparation process | |
| CN1282750C (en) | FQ-PCR diagnosis kit of WSSV and test method | |
| CN108265125A (en) | A kind of swine fever virus（CSFV）Real-time fluorescence nucleic acid isothermal amplification detection kit | |
| CN1176221C (en) | Real time fluorescent quantitative RT-PCR detecting human cell keratin 19 reagent box | |
| CN113430274B (en) | RPA primer, probe, kit and method for detecting liver enterocytozoon | |
| CN1605868A (en) | Methods for identifying animal hide and skin | |
| CN106498073A (en) | A kind of SNP marker related to Xinjiang Donkey milk production trait and its application | |
| CN1260370C (en) | Fluorescence quantificational RT-PCR detection reagent for bubble cell stomatitis virus, and preparation method | |
| CN1216291C (en) | Kit for real time fluorescence quantitative RT-RCR detection of human cancer embryoantigen | |
| CN1410546A (en) | Real time fluorescence quantitative RT-PCR detection human alpha-fetoprotein reagent box |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ANHUI PUYUAN BIOLOGY SCIENCE CO., LTD. Free format text: FORMER OWNER: HEFEI ZHONGKEDA BIOISYSTECH CO., LTD. Effective date: 20090710 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090710 Address after: Tianda high tech Zone, Hefei Road, Anhui province No. 71 yuan Huayi Science Building 5 layer C Patentee after: Anhui Jiyuan Bio-technology Co.,Ltd. Address before: College of life science, West Central School, 96 Jinzhai Road, Anhui, Hefei Patentee before: Hefei Zhongkeda Bio-technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080227 Termination date: 20210201 |